|
Sequencing of events
January 2017
EDIT CONNECT
SHARING OPTIONS:
We had a few bits
of genomic-related diagnostics news that came in just before this winter set in, from some big players like HTG Molecular Diagnostics, QIAGEN and Illumina,
as well as news from less-prominent DNA Electronics. So, before we get much farther out of 2016, we thought we’d give them some quick attention.
HTG and QIAGEN team up on precision diagnostics
TUCSON, Ariz.,
& VENLO, Netherlands—HTG Molecular Diagnostics Inc. and QIAGEN Manchester Ltd., a
wholly owned subsidiary of QIAGEN N.V., announced in late 2016 a master assay development,
commercialization and manufacturing agreement that creates a framework for both companies to combine their technological and commercial strengths with the
goal to offer pharmaceutical companies a complete next-generation sequencing (NGS)-based solution for the development and commercialization of companion
diagnostics, with a focus in oncology.
“We are very impressed with QIAGEN’s ‘sample to
insight’ philosophy and quickly envisioned development and commercial synergies through our combined efforts with pharma,” said T.J. Johnson,
HTG’s president and CEO. “Our objective is to develop a complete NGS solution from biomarker discovery to commercialized companion diagnostics,
and we believe this agreement accelerates both companies’ efforts.”
“HTG’s extraction-free
technology can add attractive capabilities to QIAGEN’s NGS-based ‘sample to insight’ solutions for applications in pathology where sample
often is limited,” said Kai te Kaat, vice president and head of franchise oncology in the Molecular Diagnostics Business Area at QIAGEN. “The
addition of HTG’s technology to our Sample to Insight GeneReader NGS system, and augmented by QIAGEN’s capabilities across NGS workflows, will
enable our pharma partners to successfully profile patients including settings where only low sample amounts are available. This capability is of interest in
many indication areas but primarily in oncology and immune-oncology applications.”
Illumina and Mayo Clinic form bioinformatics relationship
SAN DIEGO & ROCHESTER,
Minn.—Illumina Inc. recently entered into an agreement with the Mayo Clinic to make advancements in NGS technology with the intent to accelerate Mayo’s delivery
of genetic and genomic expertise.
Together, the organizations plan to integrate existing services and software
tools and employ new, innovative solutions to improve Mayo Clinic’s reporting workflows for researching inherited disease, enabling Illumina to develop
an informatics platform and knowledge base that can improve and automate genomic interpretation.
“Through
this relationship, we will be able to generate large volumes of genomic information, interrogate the data and then compare it to what’s known about
those variants and those genetic aberrations in real time, saving our geneticists time,” said Dr. William Morice II, chair of Mayo’s Department
of Laboratory Medicine and Pathology and president of Mayo Medical Laboratories. “We are pleased to work with Illumina and to leverage each
other’s expertise in genetic sequencing and analysis.”
DNAe gains
more than $50M to develop rapid diagnostics
WASHINGTON, D.C. & LONDON—The U.S. Department of
Health and Human Services’ Biomedical Advanced Research and
Development Authority recently awarded a $51.9-million contract to London-based DNA Electronics
(DNAe) to develop semiconductor-based NGS diagnostics, with a focus on antimicrobial resistant infections and influenza.
In the project, dubbed Pathogen Identification from Specimen via Capture Extraction and Sequencing, DNAe will complete development and
validation of its Genalysis platform and submit its tests for approval by the U.S. Food and Drug Administration.
“Unlike existing sequencing devices, the platform operates ‘push button’ directly from raw clinical specimens such as blood or
swabs, delivering a clinically relevant report for the physician,” said Sam Reed, president of DNAe’s U.S. office.
Code: E011723 Back |
Home |
FAQs |
Search |
Submit News Release |
Site Map |
About Us |
Advertising |
Resources |
Contact Us |
Terms & Conditions |
Privacy Policy
|